Document Classification

Section Type: RESULTS

Text: At the end of triple dosing, HCV RNA changes from baseline (mean sd log10) and proportion of patients achieving undetectable viral load (< 15 IU/ml) based on the efficacy-evaluable population were -2. 7 1. 3 (13 %), -4. 0 1. 7 (50 %), -4. 2 1. 9 (50 %), -4. 1 1. 2 (40 %), -4. 3 1. 5 (29 %) and -3. 7 1. 2 (25 %) for the 50 mg once daily, 50 mg twice daily, 100 mg once daily, 150 mg once daily, 100 mg twice daily and 200 mg once daily IDX184 doses, respectively.